Discrepancies in addressing overdose prevention through prescription monitoring programs

Drug and Alcohol Dependence

Volumn 153, Issue , 2015, Pages 355-358

  Green, Traci C ^a,c   Bowman, Sarah ^a   Davis, Corey ^b   Los, Cristina ^a   McHugh, Kimberly ^a   Friedmann, Peter D ^c  

^a INFLEXXION INC   (United States)

^b Network for Public Health Law   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

Drug policy; Overdose; Prescription monitoring programs; Prescription opioids; Unintentional poisoning

Indexed keywords

NALOXONE; NARCOTIC ANALGESIC AGENT;

ARTICLE; DEATH; DRUG OVERDOSE; DRUG SURVEILLANCE PROGRAM; HARM REDUCTION; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEALTH SERVICES RESEARCH; HUMAN; ONLINE SYSTEM; PRESCRIPTION MONITORING PROGRAM; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH; SYSTEMATIC REVIEW; THEMATIC ANALYSIS; INFORMATION RETRIEVAL; INTERNET; PRESCRIPTION; STATISTICS AND NUMERICAL DATA;

ANALGESICS, OPIOID; DRUG OVERDOSE; HARM REDUCTION; HUMANS; INFORMATION STORAGE AND RETRIEVAL; INTERNET; PRESCRIPTIONS;

EID: 84937643398     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.05.009     Document Type: Article

References (30)

1. Albert S., Brason F.W., Sanford C.K., Dasgupta N., Graham J., Lovette B. Project Lazarus: community-based overdose prevention in rural North Carolina. Pain Med. 2011, 12(Suppl. 2):S77-S85.
2. Briefing on PDMP Effectiveness 2014, Brandeis University PDMP Center of Excellence, Brandeis University, Waltham, MA.
3. Burrus R.T., Sackley W.H., Sollars D.L. Illicit drugs and economics: examples for the principles classroom. J. Econ. Financ. Educ. 2007, 6:75-86.
4. Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR 2011, 60:1487-1492. CDC.
5. CDC, 2011b. Vital signs: prescription painkiller overdoses in the U.S. 〈http://www.cdc.gov/vitalsigns/PainkillerOverdoses/index.html.〉 (accessed on 20.10.13.).
6. CDC, 2013a. Prevention status reports: prescription drug overdose. 〈http://www.cdc.gov/psr/prescriptiondrug/index.html〉 (accessed on 08.01.15.).
7. Vital signs: overdoses of prescription opioid pain relievers and other drugs among women-United States, 1999-2010. MMWR 2013, 62:537-542. CDC.
8. CDC, 2014. Vital signs: opioid painkiller prescribing. 〈http://www.cdc.gov/vitalsigns/opioid-prescribing/〉 (accessed on 08.01.15.).
9. CDC, 2015a. Injury prevention and control: prescription drug overdose-prescription drug monitoring programs. 〈http://www.cdc.gov/drugoverdose/pdmp/index.html〉 (accessed on 02.04.15.).
10. CDC, 2015b. Prescription drug overdose prevention for states. 〈 (accessed on 02.04.15.). http://www.cdc.gov/drugoverdose/states/state_prevention.html(
11. Centers for Medicaid and Medicare Services, 2014. The role of a prescription monitoring program in reducing prescription drug diversion, misuse, and abuse. 〈http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Downloads/prescriptiondrug-monitoring-factsheet.pdf〉 (accessed on 08.01.15.).
12. Coffin P.O., Sullivan S.D. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann. Intern. Med. 2013, 158:1-9.
13. Coffin P.O., Sullivan S.D. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities. J. Med. Econ. 2013, 16:1051-1060.
14. Davis C.S., Pierce M., Dasgupta N. Evolution and convergence of state laws governing controlled substance prescription monitoring programs, 1998-2011. Am. J. Public Health 2014, 104:1389-1395.
15. Delcher C., Wagenaar A.C., Goldberger B.A., Cook R.L., Maldonado-Molina M.M. Abrupt decline in oxycodone-caused mortality after implementation of Florida's Prescription Drug Monitoring Program. Drug Alcohol Depend. 2015, 150:63-68.
16. Fibbi M., Silva K., Johnson K., Langer D., Lankenau S.E. Denial of prescription opioids among young adults with histories of opioid misuse. Pain Med. 2012, 13:1040-1048.
17. Haegerich T.M., Paulozzi L.J., Manns B.J., Jones C.M. What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend. 2014, 145:34-47.
18. Li G., Brady J.E., Lang B.H., Giglio J., Wunsch H., DiMaggio C. Prescription drug monitoring and drug overdose mortality. Inj. Epidemiol. 2014, 1:9.
19. Martyres R.F., Clode D., Burns J.M. Seeking drugs or seeking help? Escalating "doctor shopping" by young heroin users before fatal overdose. Med. J. Aust. 2004, 180:211-214.
20. National Conference on State Legislatures, 2014. NCSL comments on proposed 2014 ONDCP national drug control strategy. 〈http://www.ncsl.org/research/civil-and-criminal-justice/byrne-justice-assistance-grant-byrne-jag-program.aspx〉 (accessed on 08.01.15.).
21. National Drug Control Strategy 2014 2014, Office of National Drug Control Policy, The White House, Washington, DC.
22. Paulozzi L.J., Kilbourne E.M., Desai H.A. Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011, 12:747-754.
23. Paulozzi L.J., Weisler R.H., Patkar A.A. A national epidemic of unintentional prescription opioid overdose deaths: how physicians can help control it. J. Clin. Psychiatry 2011, 72:589-592.
24. Perrone J., Nelson L.S. Medication reconciliation for controlled substances-an "ideal" prescription-drug monitoring program. N. Engl. J. Med. 2012, 366:2341-2343.
25. Reifler L.M., Droz D., Bailey J.E., Schnoll S.H., Fant R., Dart R.C., Bucher Bartelson B. Do prescription monitoring programs impact state trends in opioid abuse/misuse?. Pain Med. 2012, 13:434-442.
26. Rutkow L., Turner L., Lucas E., Hwang C., Alexander G.C. Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access. Health Aff. (Millwood) 2015, 34:484-492.
27. Utah Code, 2012. Ann. 58-37f-702.
28. Walley A.Y., Xuan Z., Hackman H.H., Quinn E., Doe-Simkins M., Sorensen-Alawad A., Ruiz S., Ozonoff A. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013, 346:f174.
29. Wodak A., 2011. Demand reduction and harm reduction. In: Global Commission on Drug Policies (Ed.), Geneva (Working Paper).
30. Yokell M.A., Green T.C., Rich J.D. Prescription drug monitoring programs. JAMA 2012, 307:912. (author reply 912-913).